EHErik B. Hysinger

Erik B. Hysinger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Erik B. Hysinger has a total of 175 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of albuterol on compliance and distensibility of the trachea and lungs

    by Chamindu C. Gunatilaka, Qiwei Xiao, Keith McConnell, Mark Sketch, Carolyn Doerning, Jasmine Hales, Angie Cummins, Ross Schierling, Ajay Kaul, Jason C. Woods, et al.

    This study introduces an in vivo swine model to simultaneously assess how albuterol alters tracheal and lung compliance. Albuterol increased compliance in both regions, potentially exacerbating airway collapse in tracheomalacia. These findings clarify the paradoxical effects of bronchodilators and emphasize the importance of individualized respiratory management for pediatric patients with airway abnormalities often mistaken for asthma.

  • Respiratory Outcomes Following Late Postnatal Dexamethasone Administration in Preterm Infants With Bronchopulmonary Dysplasia

    by Melissa House, James Rowe, Audrey Walters, Chunyan Liu, Shelley R. Ehrlich, Thomas Nienaber, Erik B. Hysinger, Paul Kingma, Shawn K. Ahlfeld

    Objective: To wean respiratory support, preterm infants with severe respiratory failure are often administered systemic corticosteroids. We sought to evaluate if postnatal age or clinical characteristics predicted death or tracheostomy following systemic dexamethasone in evolving bronchopulmonary dysplasia. Study Design: We performed a retrospective study of infants born at ≤ 30 weeks' gestational age cared for at a Level IV referral center from 2009 to 2019 who received a complete course of systemic dexamethasone beyond 4 weeks of age for the indication of preventing death and/or liberating from positive pressure ventilation. Clinical variables at the initiation of dexamethasone were examined by regression analysis, and receiver operator curves were constructed for their ability to predict death or tracheostomy. Results: Of the 81 infants that received a complete course of dexamethasone, 52% died or required tracheostomy. At onset of the dexamethasone course, infants ultimately requiring tracheostomy were more likely to be small for gestational age (SGA) ( p = 0.02), receive dexamethasone at a significantly later postmenstrual age ( p < 0.01), require higher respiratory support ( p < 0.01), and have concomitant pulmonary hypertension ( p < 0.01). The combination of SGA, a history of late bacterial sepsis, the need for multiple dexamethasone courses, a diagnosis of pulmonary hypertension, and higher respiratory support at onset of dexamethasone course predicted tracheostomy or death (AUC 0.87). Conclusion: For infants receiving systemic dexamethasone for severe respiratory failure, a combination of clinical characteristics and magnitude of respiratory support may reliably predict inability to wean from positive pressure ventilation, potentially avoiding ineffective dexamethasone exposure. Further validation is required before clinical use.


  • Pediatric Interventional Bronchoscopy—Highlighting (and Mitigating) Gaps in Care

    by Alfin Vicencio, Dirk Schramm, Erik Hysinger, Joseph Piccione, Sameera Thapa


  • Open Access

    Clinical Outcomes Through Two Years for Infants With Bronchopulmonary Dysplasia and Tracheomalacia

    by Sara M. Zak, Ina St Onge, Nara S. Higano, Alister J. Bates, Deep Gandhi, Robert J. Fleck, Paul S. Kingma, Jason C. Woods, Erik B. Hysinger

    Background: Tracheomalacia (TM) is common in infants with bronchopulmonary dysplasia (BPD) and associated with respiratory morbidity. Assessment of TM was historically via bronchoscopy, but recent studies demonstrate that ultrashort echo‐time (UTE) magnetic resonance imaging (MRI) can accurately assess TM in neonates. Research Question: Do neonates with MRI‐identified TM and BPD have increased respiratory morbidity through age 2 years? Methods: We performed an observational cohort study of 54 subjects with BPD and assessed TM using UTE MRI at term‐equivalent age. TM was defined as an airway minor/major axis ratio (r d,min ) of < 0.7. Outcomes through 2 years of life were evaluated via electronic medical record review. Results: There were 23 subjects (43%) with TM. Modified Ochiai MRI scores were similar between the subjects with and without TM (7.3 ± 4.1 vs. 7.4 ± 4.1). Subjects with TM were more likely to require respiratory support at age 2 years (62% vs. 30%, p = 0.04) and be prescribed systemic corticosteroids (71% vs. 27%, p = 0.004). Most patients with TM were prescribed bronchodilators (90% vs. 60%, p = 0.04). A 10% increase in tracheal collapse correlated with a 28‐day increased hospital length of stay ( p = 0.047), increased likelihood of pneumonia ( p = 0.05), and treatment with antibiotics ( p = 0.04) and systemic steroids ( p = 0.008). Conclusions: TM in the neonatal period was associated with increased respiratory morbidity through age 2 years, demonstrated by increased respiratory support and more frequent usage of systemic corticosteroids and bronchodilators, independent of the severity of BPD. These results highlight the significance of central airway disease in neonates with BPD.


  • Endobronchial Valves for Persistent Air Leak in Children with Necrotizing Pneumonia

    by Erik Hysinger, Laurie Murray, Faisal Shaikh, Andrew Paisley, Alfin Vicencio, Rhia Shah, Chantal Grant, Timothy J. Harkin, Andrew Haas, Pelton Phinizy, et al.


  • Transbronchial cryo‐nodal biopsies in children: A case series

    by Kubra Melike Bozkanat, Robert Wendroth, Christopher Radchenko, Gregory Burg, Erik Hysinger


  • Practices and perspectives on advanced diagnostic and interventional bronchoscopy among pediatric pulmonologists in the United States

    by A. Corcoran, D. Shore, R. P. Boesch, M. Chopra, S. Das, D. DiBardino, S. Goldfarb, A. Haas, E. Hysinger, P. Phinizy, et al.

    Introduction: Advanced diagnostic bronchoscopy includes endobronchial ultrasound (EBUS) guided transbronchial lung and lymph node biopsies, CT navigation and robotic bronchoscopy. Interventional bronchoscopy refers to procedures performed for therapeutic purposes such as balloon dilation of the airway, tissue debulking, cryotherapy, removal of foreign bodies and insertion of endobronchial valves [1]. For adult patients, these procedures are standard of care [2, 3]. Despite a lack of formalized training, there are numerous case reports and case series describing the use of advanced diagnostic and interventional bronchoscopy techniques in children. The safety and feasibility of EBUS‐TBNA, cryotherapy techniques, endobronchial valves among other techniques have been demonstrated in these publications [1, 4‐9].Methods: We sought to better understand the current practices and perspectives on interventional and advanced bronchoscopy among pediatric pulmonologists through surveys sent to pediatric teaching hospitals across the United States.Results: We received 43 responses representing 28 programs from 25 states. The highest bronchoscopy procedure volume occurred in the 0‐5 years age group. Among our respondents, 31% self‐identified as a pediatric interventional/advanced bronchoscopist. 79% believe that advanced and interventional training is feasible in pediatric pulmonology and 77% believe it should be offered to pediatric pulmonary fellows.Discussion: This is the first study to characterize current practices and perspectives regarding advanced diagnostic and interventional bronchoscopy procedures among pediatric pulmonologists in the United States. Pediatric interventional pulmonology (IP) is in its infancy and its beginnings echo those of the adult IP where only certain centers were performing these procedures.


  • Tracheomalacia Reduces Aerosolized Drug Delivery to the Lung

    by Chamindu C. Gunatilaka, Christopher McKenzie, Erik B. Hysinger, Qiwei Xiao, Nara S. Higano, Jason C. Woods, Alister J. Bates

    Rationale: Neonates with respiratory issues are frequently treated with aerosolized medications to manage lung disease or facilitate airway clearance. Dynamic tracheal collapse (tracheomalacia [TM]) is a common comorbidity in these patients, but it is unknown whether the presence of TM alters the delivery of aerosolized drugs. Objectives: To quantify the effect of neonatal TM on the delivery of aerosolized drugs. Methods: Fourteen infant subjects with respiratory abnormalities were recruited; seven with TM and seven without TM. Respiratory-gated 3D ultrashort echo time magnetic resonance imaging (MRI) was acquired covering the central airway and lungs. For each subject, a computational fluid dynamics simulation modeled the airflow and particle transport in the central airway based on patient-specific airway anatomy, motion, and airflow rates derived from MRI. Results: Less aerosolized drug reached the distal airways in subjects with TM than in subjects without TM: of the total drug delivered, less particle mass passed through the main bronchi in subjects with TM compared with subjects without TM (33% vs. 47%, p = 0.013). In subjects with TM, more inhaled particles were deposited on the surface of the airway (48% vs. 25%, p = 0.003). This effect becomes greater with larger particle sizes and is significant for particles with a diameter >2 μm (2–5 μm, p ≤ 0.025 and 5–15 μm, p = 0.004). Conclusions: Neonatal patients with TM receive less aerosolized drug delivered to the lungs than subjects without TM. Currently, infants with lung disease and TM may not be receiving adequate and/or expected medication. Particles >2 μm in diameter are likely to deposit on the surface of the airway due to anatomical constrictions such as reduced tracheal and glottal cross-sectional area in neonates with TM. This problem could be alleviated by delivering smaller aerosolized particles.